Catalyst Pharma Has Announced An Exclusive North America Licensing Agreement For Santhera Pharmaceuticals' Duchenne Muscular Dystrophy Candidate, Vamorolone; Catalyst Will Pay $75M Upfront And A Concurrent Equity Investment Of $15M
Portfolio Pulse from Benzinga Newsdesk
Catalyst Pharma has entered into an exclusive licensing agreement with Santhera Pharmaceuticals for its Duchenne Muscular Dystrophy (DMD) candidate, Vamorolone. Catalyst will pay $75 million upfront and make a concurrent equity investment of $15 million.
June 20, 2023 | 10:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catalyst Pharma's exclusive licensing agreement with Santhera Pharmaceuticals for Vamorolone may boost its stock price in the short term.
Catalyst Pharma's exclusive licensing agreement for Vamorolone, a Duchenne Muscular Dystrophy candidate, may lead to potential revenue growth and market expansion. The $75M upfront payment and $15M equity investment show commitment and confidence in the product, which may positively impact CPRX's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100